Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies
| Autor: | Anjisnu Banerjee, Timothy S. Fenske, Malika Siker, Gerald J. Harris, Gregory J. Griepentrog, Beth Erickson, Narendranath Epperla, Parameswaran Hari, Timothy S. Wells, Sridevi Ramalingam, Mehdi Hamadani, Binod Dhakal, Paul Hosking, Jamie Shuff, Nirav N. Shah, Lisa Rein, Anita D'Souza |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Lymphoma Lymphoproliferative disorders Kaplan-Meier Estimate Gastroenterology Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine Medicine Humans Young adult Aged Proportional Hazards Models Retrospective Studies Aged 80 and over business.industry Proportional hazards model Eye Neoplasms Hazard ratio food and beverages Retrospective cohort study Hematology Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease digestive system diseases Confidence interval Surgery Log-rank test 030104 developmental biology Treatment Outcome Oncology 030220 oncology & carcinogenesis Cohort Female business |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 17(5) |
| ISSN: | 2152-2669 |
| Popis: | Introduction Ocular adnexal lymphoproliferative disorders (OALDs) are almost exclusively of B-cell origin, with the majority being extra-nodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). The comparative efficacy of involved field radiation therapy (IFRT) in MALT vs. non-MALT OALDs is not known. Materials and Methods We present a single-center, large cohort, retrospective study of the efficacy of IFRT in OALDs. Failure-free survival (FFS), complete remission, and local, regional, and distant failure were determined for 112 patients with MALT OALDs (n = 71) and non-MALT OALDs (n = 41) cohorts. Results Fifty-six patients with MALT OALD and 26 patients with non-MALT OALD received IFRT only (without any planned concurrent or sequential systemic chemothereapy or chemo-immunotherapies). Among the OALD cohorts treated with only IFRT, complete remission was achieved in 49 (87.5%) patients in the MALT cohort and 23 (88.4%) in the non-MALT cohort ( P = .99). Clinically, resolution of symptoms occurred in 83.3% and 93.3% of the patients in the MALT and non-MALT cohorts, respectively. Local failure occurred in 4 (7.1%) patients in the MALT cohort, compared with 4 (15.3%) patients in the non-MALT cohort ( P = .24). Regional failure (or extra-orbital failure) occurred in 5 (8.9%) patients in the MALT cohort and in 3 (11.5%) patients in the non-MALT cohort ( P = .71). Distant failure was reported in 1 (1.7%) and 2 patients (7.6%) in the MALT and non-MALT cohorts, respectively ( P = .18). The median follow-up of survivors was 5.1 years (range, 0.1-22.5 years) in the MALT cohort and 3.9 years (range, 0.1-22.9 years) in the non-MALT cohort. The 5-year and 10-year FFS was 95% (95% confidence interval [CI], 88%-100%) and 83% (95% CI, 70%-98%) for the ocular MALT and 67% (95% CI, 48%-94%) and 56% (95% CI, 34%-91%) for the non-MALT cohorts, respectively (log rank for P = .025). On multivariate analyses, age (hazard ratio [HR], 1.06; 95% CI, 1.10-1.12; P = .03), presence of non-MALT histology (HR, 13.9; 95% CI, 2.05-94.4; P = .007), and radiation dose P = .03) were associated with worse FFS. The 5-year and 10-year overall survival was 92% (95%, CI 83%-100%) and 80% (95% CI, 66%-96%) for the MALT and 78% (95% CI, 61%-100%) and 62% (95% CI, 38%-100%) for the non-MALT cohorts, respectively ( P = .80). Conclusion Our results reveal that IFRT provided excellent disease control with superior FFS in the MALT cohort when compared with the non-MALT group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect